Cardinal Health Extends CVS Distribution Pact; Reaffirms FY27 EPS Guidance

What Happened

• On October 1, 2026, Cardinal Health, Inc. announced it entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032. The company issued the disclosure under Regulation FD via a news release (included as Exhibit 99.1 to the 8‑K).
• Cardinal Health also reaffirmed its previously issued fiscal year 2027 non‑GAAP earnings per share guidance of $12.40 to $12.60 and its long‑term non‑GAAP EPS growth target of 12% to 14%.

Key Details

• Date of disclosure: October 1, 2026 (filed on Form 8‑K).
• Counterparty: CVS Health; extension covers pharmaceutical distribution agreements through June 2032.
• FY2027 non‑GAAP EPS guidance: $12.40 – $12.60 (reaffirmed).
• Long‑term non‑GAAP EPS growth guidance: 12% – 14% (reaffirmed).

Why It Matters

• The binding LOI to extend distribution agreements with CVS secures a major customer relationship and increases revenue and earnings visibility for Cardinal Health through mid‑2032.
• Reaffirming FY27 and long‑term non‑GAAP EPS guidance signals management expects to meet prior financial targets and reflects confidence in the company’s near‑term outlook.
• This filing is a Regulation FD disclosure (news release) and does not present new financial statements; investors should monitor for any definitive contracts or later filings that provide further details.